Biotalys NV (BTLS) - Net Assets
Based on the latest financial reports, Biotalys NV (BTLS) has net assets worth €19.81 Million EUR (≈ $23.16 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€28.98 Million ≈ $33.89 Million USD) and total liabilities (€9.18 Million ≈ $10.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Biotalys NV asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €19.81 Million |
| % of Total Assets | 68.35% |
| Annual Growth Rate | 52.21% |
| 5-Year Change | 7.63% |
| 10-Year Change | N/A |
| Growth Volatility | 314.67 |
Biotalys NV - Net Assets Trend (2018–2024)
This chart illustrates how Biotalys NV's net assets have evolved over time, based on quarterly financial data. Also explore how large is Biotalys NV's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Biotalys NV (2018–2024)
The table below shows the annual net assets of Biotalys NV from 2018 to 2024. For live valuation and market cap data, see Biotalys NV (BTLS) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €27.61 Million ≈ $32.27 Million |
+7.96% |
| 2023-12-31 | €25.57 Million ≈ $29.89 Million |
-32.91% |
| 2022-12-31 | €38.11 Million ≈ $44.56 Million |
-35.31% |
| 2021-12-31 | €58.91 Million ≈ $68.88 Million |
+129.71% |
| 2020-12-31 | €25.65 Million ≈ $29.99 Million |
+21.71% |
| 2019-12-31 | €21.07 Million ≈ $24.64 Million |
+849.66% |
| 2018-12-31 | €2.22 Million ≈ $2.59 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biotalys NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 396200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €5.54 Million | 20.07% |
| Other Components | €33.79 Million | 122.40% |
| Total Equity | €27.61 Million | 100.00% |
Biotalys NV Competitors by Market Cap
The table below lists competitors of Biotalys NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MICROPORT CARDIO.MEDTECH.
F:72X
|
$107.57 Million |
|
LIG-ES SPAC
KQ:220260
|
$107.63 Million |
|
Samyang Tongsang Co. Ltd.
KO:002170
|
$107.70 Million |
|
W5 Solutions AB
ST:W5
|
$107.71 Million |
|
Loop Telecommunication International Inc
TW:3025
|
$107.43 Million |
|
Hotron Precision Electronic Industrial Co Ltd
TW:3092
|
$107.42 Million |
|
Donegal Group B Inc
NASDAQ:DGICB
|
$107.30 Million |
|
Uniquest
KO:077500
|
$107.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biotalys NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 25,569,000 to 27,605,000, a change of 2,036,000 (8.0%).
- Net loss of 13,188,000 reduced equity.
- New share issuances of 14,549,000 increased equity.
- Other comprehensive income decreased equity by 4,083,000.
- Other factors increased equity by 4,758,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-13.19 Million | -47.77% |
| Share Issuances | €14.55 Million | +52.7% |
| Other Comprehensive Income | €-4.08 Million | -14.79% |
| Other Changes | €4.76 Million | +17.24% |
| Total Change | €- | 7.96% |
Book Value vs Market Value Analysis
This analysis compares Biotalys NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.27x to 3.61x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €0.70 | €3.00 | x |
| 2020-12-31 | €0.85 | €3.00 | x |
| 2021-12-31 | €1.93 | €3.00 | x |
| 2022-12-31 | €1.23 | €3.00 | x |
| 2023-12-31 | €0.81 | €3.00 | x |
| 2024-12-31 | €0.83 | €3.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biotalys NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.33x
- Recent ROE (-47.77%) is above the historical average (-49.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -36.40% | 0.00% | 0.00x | 1.31x | €-9.78 Million |
| 2020 | -41.91% | 0.00% | 0.00x | 1.41x | €-13.31 Million |
| 2021 | -28.73% | 0.00% | 0.00x | 1.19x | €-22.82 Million |
| 2022 | -59.64% | 0.00% | 0.00x | 1.30x | €-26.54 Million |
| 2023 | -80.21% | 0.00% | 0.00x | 1.43x | €-23.07 Million |
| 2024 | -47.77% | 0.00% | 0.00x | 1.33x | €-15.95 Million |
Industry Comparison
This section compares Biotalys NV's net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $639,400,000
- Average return on equity (ROE) among peers: 4.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biotalys NV (BTLS) | €19.81 Million | -36.40% | 0.46x | $107.45 Million |
| Tessenderlo (TESB) | $639.40 Million | 4.00% | 1.21x | $1.50 Billion |
About Biotalys NV
Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6… Read more